Document:

CONFIDENTIAL TREATMENT
REQUESTED .  Confidential portions of this document have been redacted
and have been separately filed with the Commission.

    
 

    Exhibit
10.44

     

    RESEARCH AND LICENSE
AGREEMENT

     

    Between

     

    YEDA RESEARCH AND
DEVELOPMENT COMPANY LIMITED

     

    a company
duly registered under the laws of Israel

    of P.O.
Box 95, Rehovot 76100, Israel (“Yeda”)

     

    and

     

    MOR RESEARCH APPLICATIONS
LTD.

     

    a company
duly registered under the laws of Israel

    of 23
Hasivim Street., Kiryat Matalon, P.O. Box 7590

    Petach
Tikva 49170 (“Mor”)

     

    and

     

    HAVERFIELD
LTD.

     

    a company
duly registered under the laws of Gibraltar and

    having
its principal place of business at Valmet Nominees

    Limited
Suites 7B & 8B 50
Town Range Gibraltar

     

    (the
“Company”)

     

    and

     

    BIOGAL ADVANCED
BIOTECHNOLOGY LTD

     

    A company
duly registered under the laws of the State of

    Israel
and having its principal place of business at 3 Hayezira

    St. Shap
House, Ramat Gan, Israel 52521 (“Biogal Israel”)

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    WHEREAS:

     

    
      	
               
      

            	
              A.

            	
              In
      the course of conducting research and primary clinical observations,
      Professor Moshe Mittleman of Rabin Medical Center, Hasharon Hospital,
      Petach- Tikva (“RMC”) and Professor
      Nechama Haran-Ghera of the department of Immunology of the Weizmann
      Institute of Science, Rehovot (the “Institute”), have discovered the
      positive effects of the use of recombinant human erythropoietin (“EPO”) as a factor that
      may lead to tumor regression in the treatment of myeloma cancer, all as
      more particularly described in the patent abstract entitled
      “Pharmaceutical Compositions Comprising Erythropoietin for Treatment of
      Cancer”, attached hereto as Attachment A, and
      forming the basis of certain patent applications submitted in different
      jurisdictions and listed in an appendix attached hereto as Attachment B (the “Existing Patent
      Applications”, as further defined below). The inventions covered by
      the Existing Patents Applications, and all associated discoveries,
      products, materials, methods, processes, procedures, techniques, know-how,
      data, formulas, clinical and preclinical results (if any), analytical
      reference materials, chemical substance and other information shall be
      collectively referred to as the “Existing
      Technology”.

            

    

     

    
      	
               
      

            	
              B.

            	
              Yeda
      and Mor are the joint owners, in accordance with the Ownership Breakdown
      (as described in Section 6 below) of the Existing Technology (Yeda and Mor
      shall be collectively referred to as the “Licensors”);

            

    

     

    
      	
               
      

            	
              C.

            	
              The
      Licensors are interested in entering into an agreement with a party having
      an ability and willingness to (i) finance the performance of certain
      initial research (“the
      Initial Research”) under the leadership of Professor Nechama
      Haran-Ghera (“Prof.
      Haran-Ghera”) and Professor Moshe Mittleman (“Prof. Mittelman”) (Prof.
      Haran-Ghera and Prof. Mittelman shall be collectively referred to as
      “the Chief
      Investigators”) as more fully described in the research programs
      attached hereto as Attachment Cl for the
      Research at the Institute (as defined below) and Attachments C2 for the
      Initial Clinical Research (as defined below) (“the Initial Research
      Program”) and any further research that will be needed to
      accomplish the objectives hereunder (collectively called the “Research”); and to (ii)
      pursue clinical studies in order to obtain approval from appropriate
      governmental agencies for marketing drugs based upon EPO for the treatment
      in human patients of certain types of cancer that are covered by the
      license(s) granted to the Company hereunder, as further detailed in
      Section 8 herein (the “Product” or “Products”); and (iii) to
      the extent to which such rights are covered by an applicable Patent, to
      manufacture and market the Products;
and

            

    

     

    
      	
               
      

            	
              D.

            	
              The
      Company represents and warrants that it has such ability and wishes to
      enter into an agreement as aforesaid with the Licensors, according to
      which the Licensors shall grant the Company and the Company shall accept
      from the Licensors a worldwide, exclusive license to use the Licensed
      Information (as such term is hereinafter defined) for the manufacture,
      production, marketing and sale of the Products, all in accordance with,
      and subject to, the terms and conditions set forth in this Agreement;
      and

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
               
      

            	
              E.

            	
              Yeda
      and Mor are willing to procure the performance of the Initial Research,
      each with respect to that portion of the Initial Research as is detailed
      in Section 2 below, and subject to and in accordance with the terms and
      conditions of this Agreement; and

            

    

     

    
      	
               
      

            	
              F.

            	
              By
      operation of Israeli law and/or under the terms of employment of Prof.
      Haran-Ghera at the Institute and/or pursuant to an agreement between the
      Institute, Yeda and Prof. Haran-Ghera, all right, title and interest of
      Prof. Haran-Ghera’s or the Institute’s in and to the Licensed Information,
      and in any results deriving from the performance of the Research at the
      Institute (as defined below in Section 2.2) are and shall be the sole
      property of Yeda; and

            

    

     

    
      	
               
      

            	
              G.

            	
              By
      operation of Israeli law and/or under the terms of employment of Prof.
      Mittleman, all right, title and interest of Prof. Mittleman’s in and to
      the Licensed Information, and in any results deriving from the performance
      of the Initial Clinical Research (as defined below in Section 2.3) are and
      shall be the sole property of Mor.

            

    

     

    NOW
THEREFORE IT IS AGREED BETWEEN THE PARTIES HERETO AS FOLLOWS:

     

    
      	
              1.

            	
              Preamble,
      Appendices and
Interpretation

            

    

     

    
      	
              1.1

            	
              The
      Preamble and Attachments hereto form an integral part of this
      Agreement.

            

    

     

    
      	
              1.2.

            	
              In this Agreement
      the terms below shall bear the meanings assigned to them below,
      unless the context shall indicate a contrary
      intention:

            

    

     

    
      	
            	
              1.2.1

            	
              “Affiliated Entity” -
      shall mean a person, company, corporation, partnership or other entity
      (hereinafter collectively (an “Entity”) which directly or indirectly, is
      controlled by, or controls, or is under common control with, another
      entity. For the purposes of this definition, “control” shall mean the
      ability, directly or indirectly, to direct the activities of the relevant
      entity and includes without limitation the holding, directly or
      indirectly, of 50% (fifty percent) or more of the issued share capital or
      of the voting power of the relevant entity or the holding, directly or
      indirectly, of a right to appoint 50% (fifty percent) or more of the
      directors of such entity;

            

    

     

    
      	
            	
              1.2.2

            	
              The
      “Biogal Group”
      shall mean the Company and Biogal
Israel.

            

    

     

    
      	
            	
              1.2.3

            	
              The
      “Effective Date”
      shall mean the date of execution of this Agreement and the Founders
      Agreement by all of the parties
hereto.

            

    

     

    
      	
            	
              1.2.4

            	
              An
      “Entitling Event”
      - shall mean any of the following: (i) the issuance of shares of any class
      (including securities convertible to shares) of the Company which grant
      the holder(s) thereof 50% or more of the issued and outstanding share
      capital of the Company or of any means of control of the Company; or (ii)
      a consolidation, merger or reorganization of the Company with or into
      another entity, or (iii) a sale or an assignment (other than to an
      Affiliated Entity) of all or substantially all of the Company’s assets, or
      substantially all of the Company’s issued and outstanding capital stock,
      or the granting of an exclusive license in all or substantially all of the
      Company’s strategic assets (other than the granting of such license to an
      entity within the Biogal Group or an Affiliated Entity thereof) in which
      the consideration for the granting of such license is payable in whole or
      in part in one or more payments in cash or cash equivalent (provided that
      a bona fide transaction with a third party in which the sole consideration
      for the granting of such a license shall be royalties based upon future
      sales of Products shall not be deemed an “Entitling Event” hereunder). For
      the purposes of this definition, references to the Company shall include
      any member of the Biogal Group and/or any successor or assign thereof
      and/or an Affiliated Entity thereof that is a Sublicensee pursuant to
      Section 9 below.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
            	
              1.2.5

            	
              “First Commercial Sale”
      shall mean the first commercial sale of a Product in any country. For the
      purposes of this definition, “commercial sale” shall not include a sale
      for an experiment or for test market purposes or for the purposes of use
      at a clinical trial.

            

    

     

    
      	
            	
              1.2.6

            	
              “Founders Agreement”
      shall mean the founders agreement executed concurrently with this
      Agreement by the founders of the Company, including among others,
      Mor.

            

    

     

    
      	
            	
              1.2.7

            	
              The
      “Initial Research
      Budget” - shall mean the research budgets, expressed in U.S.
      Dollars, attached hereto as Attachment DI for the Research at the
      Institute (as defined below) and Attachment D2 for the Initial Clinical
      Research (as defined below), as such budgets may be amended, if amended,
      by written agreement between the
parties;

            

    

     

    
      	
            	
              1.2.8

            	
              The
      “Initial Research
      Period” - shall mean, with respect to the Research at the Institute
      (as defined below) the period commencing on the date hereof and ending
      thirteen (13) months thereafter, or as extended or shortened by written
      agreement of the parties hereto and with respect to the Initial Clinical
      Research (as defined below) the period commencing on the date hereto and
      ending eighteen (18) month thereafter, or as extended or shortened by
      written agreements of the parties
hereto;

            

    

     

    
      	
            	
              1.2.9

            	
              The
      “License” - shall
      mean the license granted to the Company by Yeda and Mor pursuant to
      Section 8 below;

            

    

     

    
      	
            	
              1.2.10

            	
              The
      “Licensed
      Information” - shall mean the Existing Patent Applications, the
      Existing Technology and all and any inventions, discoveries, products,
      materials, methods, formulas, processes, procedures, techniques, know-how,
      trade secrets, data, information and other results whatsoever, which are
      discovered or developed in the course of the Research and any development
      activities financed or performed by the Company or by any other member of
      Biogal Group during the period of the License, and any patent application
      filed or issued in respect of the above and any drawings, plans, diagrams,
      specification and other documents or files including computer files
      containing any of the above.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
            	
              1.2.11

            	
              The
      “Patents” - shall
      mean the Existing Patents Applications and other patent applications or
      applications for certificates of invention covering any portion of the
      Licensed Information, as well as all continuations, continuations-in-part,
      patents of addition, divisions and renewals thereof, and all patents or
      certificates of invention which may be granted on any of the foregoing,
      and all reissues and extensions
thereof.

            

    

     

    
      	
            	
              1.2.13

            	
              “Product Approval” -
      shall mean an approval given by the U.S. Food and Drug Administration for
      the marketing of the Product.

            

    

     

    
      	
            	
              1.2.14

            	
              “Sublicensee” - shall
      mean any permitted sublicensee under the License, in accordance with the
      provisions of Section 9.

            

    

     

    
      	
              1.3

            	
              The
      headings in this Agreement are intended solely for convenience or
      reference and shall be given no effect in the interpretation of this
      Agreement.

            

    

     

    
      	
              2. 

            	
              The
      Research

            

    

     

    
      	
              2.1

            	
              The
      Company undertakes to fund and pursue the Initial Research in accordance
      with the terms contained herein, and to make its reasonable commercial
      efforts to actively pursue the performance of the Research, and to secure
      funding for the Research. The parties hereto acknowledge that the
      administration of the Company’s research and development activities in
      Israel shall be performed by Biogal Israel, as a sublicensee of the
      Company, pursuant to the terms and conditions of the Sublicense Agreement
      executed concurrently with this Agreement by and between the Company and
      Biogal Israel, attached hereto as Attachment E. The
      Parties hereto acknowledge that the financing of the Company’s research
      and development activities in Israel shall be performed by the Company and
      that the Company and Biogal Israel shall be jointly and severally liable
      for such financing. The Initial Research shall be performed at the
      Institute and certain hospitals and medical institutes as set forth in the
      Initial Research Program, and within the framework of the Initial Research
      Budget. The Initial Research Budget with regard to the Research at the
      Institute shall consist of one thirteen (13) month period and payments for
      the performance of the Research at the Institute shall be made in four
      installments, as follows (i) for the first nine-month period of the
      Initial Research, payment shall be made for each three month period in
      advance; and (ii) for the last four month period of the Initial Research,
      payment shall be made in one installment in advance. The Initial Research
      Budget with regard to the Initial Clinical Research shall consist of one
      eighteen (18) month period, and payments for the performance of the
      Initial Research Budget shall be made for each three (3) month period in
      advance.

            

    

     

    
      	
              2.2

            	
              Subject
      to the terms and conditions hereof, Yeda undertakes to procure the
      performance of the laboratory portion of the Initial Research designated
      to be performed at the Institute according to the Initial Research Program
      (the “Research at the
      Institute”), under the supervision of Prof. Haran-Ghera provided
      however that the fact that Prof. Haran-Ghera shall cease to be available
      for the supervision of the performance of the Research at the Institute
      shall not constitute a breach of this Agreement by Yeda. In such event,
      Yeda shall make its reasonable effort to find from amongst the scientists
      of the Institute a replacement scientist acceptable to the Company (such
      acceptance to be in writing, and not to be unreasonably withheld) to
      continue the supervision of the Research at the Institute, provided
      however that Yeda does not undertake to find such a replacement. If no
      replacement scientist acceptable to both parties is found within 30
      (thirty) days of the date on which Prof. Haran-Ghera ceases to supervise
      the Research at the Institute, the Company shall be entitled, by written
      notice to Yeda, to terminate the Research at the Institute, and the
      Initial Research Period shall terminate with respect to the Research at
      the Institute upon the expiration of 60 (sixty) days from the date of
      receipt by Yeda of such written notice. Upon such termination, Yeda shall
      be released from any obligation to procure the performance of the Research
      at the Institute and the Company shall be released from any obligation to
      finance the Research at the Institute with respect to the period following
      such termination. The termination of the provisions relating to the
      performance and financing of the Research at the Institute shall not
      affect the validity of the remaining terms and provisions of this
      Agreement, including, without limitation, with respect to the License
      granted to the Company pursuant to Section 8 hereto, the Company’s
      obligation to pay Compensation pursuant to Section 10 below, and the
      continuation of the Initial Clinical Research (as defined in Section 2.3
      below). To avoid doubt, in the event that the provisions relating to the
      performance and financing of the Research at the Institute have been
      terminated as provided herein, the Company shall be entitled to freely
      pursue such research as it deems fit outside of the
    Institute.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              2.3

            	
              Subject
      to the terms and conditions hereof, Mor undertakes to procure the conduct
      of the clinical portion of the Initial Research at hospitals or medical
      institutes, as set forth in the Initial Research Program (the “Initial Clinical
      Research”), and under the supervision of Prof. Mittleman, provided
      however that the fact that Prof. Mittleman shall cease to be available for
      the supervision of the performance of the Initial Clinical Research shall
      not constitute a breach of this Agreement by Mor. In such event, Mor shall
      attempt to find a replacement scientist acceptable to the Company (such
      acceptance to be in writing, and not to be unreasonably withheld) to
      continue the supervision of the Initial Clinical Research, provided
      however that Mor does not undertake to find such a replacement. If no
      replacement scientist acceptable to both parties is found within 30
      (thirty) days of the date on which Prof. Mittleman has ceased to supervise
      the Research at the Institute, the Company shall be entitled, by written
      notice to Mor, to terminate the Initial Clinical Research, and the Initial
      Research Period shall terminate with respect to the Initial Clinical
      Research upon the expiration of 60 (sixty) days from the date of receipt
      by Mor of such written notice. Upon such termination, Mor shall be
      released from any obligation to procure the performance of the Initial
      Clinical Research and the Company shall be released from any obligation to
      finance the Initial Clinical Research with respect to the period following
      such termination. The termination of the provisions relating to the
      performance and financing of the Initial Clinical Research shall not
      affect the validity of the remaining terms and provisions of this
      Agreement, including, without limitation, with respect to the License
      granted to the Company pursuant to Section 8 hereto, the Company’s
      obligation to pay Compensation pursuant to Section 10 below, the
      continuation of the Research at the Institute and the continuation of the
      clinical portion of the Research in other medical institutes or hospitals
      under the supervision of another
scientist.

            

    

     

    
      	
              2.4

            	
              The
      Company shall make payments to Yeda and Mor in consideration of the
      performance of the Research at the Institute and the Initial Clinical
      Research in accordance with the Initial Research Budget. All such payments
      shall be made in US Dollars at such times and in such amounts as are set
      forth in the Initial Research Budget or in the Research Budget (as defined
      in Section 2.5. below), as
applicable

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              2.5

            	
              It
      is agreed that at the request from time to time of the Chief Investigators
      or any party hereto, the parties shall consult with a view to considering
      the advisability of variations in the Initial Research Program and/or in
      the Initial Research Budget. Such variations approved by the parties in
      writing shall constitute amendments to the Initial Research Program and/or
      in the Initial Research Budget, as applicable. Without limiting the
      generality of the foregoing, the parties agree, no fewer than thirty (30)
      days prior to the end of the Initial Research Period, to consult in good
      faith concerning an extension of the Initial Research Period for a further
      one-year period. If, as a result of such consultation, the parties agree
      to extend the Initial Research Period, and agree upon a research program
      and a budget in respect thereof, the Initial Research Period shall be
      extended by such one-year period (the “Extended Research
      Period”), and such research program and budget shall be deemed the
      “Research program” and the “Research Budget” for such year. This process
      shall thereafter be repeated annually for each of the following one-year
      periods after the termination of each one-year period of the Extended
      Research Period. Nothing herein contained shall be interpreted as imposing
      on either party any obligation to agree to any such amendment, extension,
      research program or budget.

            

    

     

    
      	
              2.6

            	
              Charges
      in respect of research expenditures made by the Licensors shall be made in
      accordance with the procedures then prevailing at the Institute or at Mor,
      as applicable, for charging research expenditures to individual projects
      of applied research. The Company acknowledges and is aware that the
      Institute’s internal regulations and procedures and the internal
      regulations and procedures of Mor and its affiliated medical institutions
      require that a portion of research funding received from external sources
      be allocated to cover overhead expenses, and that amounts to paid to the
      Institute and Mor in connection with the Initial Research (and any
      subsequent research performed by them) will be subject to such regulations
      and procedures, as set forth in the Initial Research
    Budget.

            

    

     

    
      	
              3.

            	
              Reporting

            

    

     

    
      	
              3.1

            	
              Yeda
      shall procure the submission by Prof. Haran-Ghera to the Company of an
      interim written report on the progress and the results deriving from the
      Research at the Institute covering each ***** period during the Initial
      Research Period and any Extended Research Period thereafter, within *****
      of the end of  each such ***** period, and of a written report
      summarizing the final results of the Research at the Institute within
      ***** of the end of the Initial Research Period or any Extended Research
      Periods thereafter (as applicable). Yeda will notify the Company of any
      significant event or results of which it shall become aware (including,
      without limitation, any invention) arising out of the Research at the
      Institute during the course of any such ***** period. In addition, Yeda
      shall submit to the Company, with respect to each ***** period of the
      Initial Research Period and any Extended Research Period thereafter, a
      separate financial report setting forth the monies received and expended
      by it in connection with the Research at the Institute during such *****
      period. Each report as aforesaid shall be submitted to the Company not
      later than ***** after the end of the period covered by such report. In
      the event of a delay exceeding ***** of the submission of any of the
      reports mentioned above, the Company shall have the right to postpone the
      payments for the Research at the Institute, as set forth in the Initial
      Research Budget or in the Research Budget (as applicable), until such
      delayed report shall be submitted to the Company in
  full.

            

    

     

    
      

    

    
      * *****Confidential material redacted and filed separately
with the Commission.

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              3.2

            	
              Mor
      shall procure the submission by Prof. Mittleman to the Company of an
      interim written report on the progress and the results deriving from the
      Initial Clinical Research covering each ***** period of the Initial
      Research Period and any Extended Research Period thereafter, within *****
      of the end of each such ***** period, and of a written report summarizing
      the final results of the Initial Clinical Research within ***** of the end
      of the Initial Research Period or any Extended Research Period thereafter
      (as applicable). Mor will notify the Company of any significant event or
      results of which it shall become aware (including, without limitation, any
      invention) arising out of the Initial Clinical Research during the course
      of any such ***** period. In addition, Mor shall submit to the Company,
      with respect to each ***** period of the Initial Research Period and any
      Extended Research Period thereafter, a separate financial report setting
      forth the monies received and expended by it in connection with the
      Initial Clinical Research during such ***** period. Each report as
      aforesaid shall be submitted to the Company not later than ***** after the
      end of the period covered by such report. In the event of a delay
      exceeding ***** of the submission of any of the reports mentioned above,
      the Company (or any other company in the Bio-Gal Group) shall have the
      right to postpone the payments for the Initial Clinical Research, as set
      forth in the Initial Research Budget or in the Research Budget (as
      applicable), until such delayed report shall be submitted to the Company
      in full.

            

    

     

    
      	
              4.

            	
              No
      Warranties

            

    

     

    
      	
              4.1

            	
              The
      Licensors make no warranties whatsoever as to the Licensed Information,
      including, without limitation, regarding the success or results of the
      Initial Research, or the scope and validity of the Existing Patent
      Applications and/or the Patents (if any) and/or the chances of receiving
      approval for Existing Patent Application or future application in any
      jurisdiction and/or that the use and exploitation of the Licensed
      Information and the exercise of any rights of the License under this
      Agreement, including the development of any Product as contemplated
      hereunder, will not infringe any third party’s rights and/or with respect
      to the technical or commercial feasibility of developing any Product on
      the basis of the Licensed Information and/or receiving Product Approval
      for any such Product.

            

    

     

    
      	
              4.2

            	
              Without
      derogating from the foregoing, the parties hereto acknowledge that Johnson
      & Johnson and Hoffman Laroche currently possess one or more patents
      covering the manufacture of EPO (which the Company believes will expire
      prior to 2005), and that the production and marketing of the Products may
      be dependent, upon securing an arrangement with Johnson & Johnson and
      Hoffman Laroche for the purchase and/or production of EPO for
      incorporation in the Products.

            

    

     

    
      	
              5.

            	
              Development
      and Commercialization

            

    

     

    
      	
              5.1

            	
              The
      Company will use reasonable efforts to develop, manufacture, produce,
      market and sell the Products throughout the world during the term of the
      License. For such purpose, and without derogating from the generality of
      the foregoing, the Company undertakes to use reasonable efforts to perform
      the activities described in the development program attached hereto as
      Attachment F, (the “Development Program”, including all additions or
      amendments made by written agreement of the parties hereto) with respect
      to the development, for the purpose of manufacture and marketing, of the
      Products, including the timetable for the completion of the various stages
      of such development.

            

    

    
       

      
        

      

      
        * *****Confidential material redacted and filed separately
with the Commission. 

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              5.2

            	
              The
      Company shall provide the Licensors with written reports on the progress
      and results of the Development Program with respect to each Product. Prior
      to the First Commercial Sale of each such Product, such reports shall be
      made once every six (6) months. The Company shall notify the Licensors as
      soon as practicable of any significant results arising out of the said
      Development Program during any six (6) month
  period.

            

    

     

    
      	
              5.3

            	
              For
      the removal of doubt, nothing contained in this Agreement shall be
      construed as a warranty by the Company that the Development Program to be
      carried out by it as aforesaid will achieve its aims and the Company makes
      no warranties whatsoever as to any results to be achieved in consequence
      of the carrying out of such Development
Program.

            

    

     

    
      	
              6.

            	
              Title

            

    

     

    
      	
              6.1

            	
              Subject
      only to the License, all right, title and interest in and to the Licensed
      Information and in and to the Patents, and all right, title and interest
      in and to any drawings, plans, diagrams, specifications, other documents,
      models or any other physical matter in any way containing, representing or
      embodying any of the Licensed Information, is and shall be the exclusive
      property of the Licensors, whose respective rights, title and interest in
      the same, as between themselves, shall be divided as follows: ***** (the
      “Ownership
      Breakdown”).

            

    

     

    
      	
               
      

            	
              For
      the avoidance of doubt, the Licensors shall retain exclusive ownership
      (according to the Ownership Breakdown) of all right, title and interest in
      any and all discoveries, inventions, results, and works of authorship made
      during the Research by any person or entity, as well as any modifications,
      applications and derivates thereof.

            

    

     

    
      	
              7.

            	
              Patents;
      Patent Infringements

            

    

     

    
      	
              7.1

            	
              At
      the initiative of any party hereto, the parties shall consult with one
      another in good faith regarding the filing of patent applications (such
      term herein to include any applications for continuations,
      continuations-in-part, divisions, patents of addition or renewals) in
      respect of any portion of the Licensed Information including, but without
      limitation, the jurisdictions in which such applications should be filed,
      the timing of the filing of such applications and the contents thereof and
      regarding any other applications or filings giving similar statutory
      protection to such Licensed Information. Following such consultations, the
      Licensors shall, at the Company’s written request, prepare, file and
      prosecute patent applications as aforesaid in such jurisdiction or
      jurisdictions as shall be specified in the Company’s said request and, in
      addition, the Licensors shall make reasonable efforts to prosecute the
      Existing Patent Applications and maintain and protect at the applicable
      patent office the existing patents, if any, all the above provided that
      the Company shall have previously secured, to the satisfaction of the
      Licensors, the payment by the Company of the amounts of all costs and fees
      involved with such preparation, filing, prosecution, maintenance and
      protection. The Parties agree that their joint policy will be to seek a
      comprehensive patent protection for all Licensed Information licensed to
      the Company hereunder.

            

    

     

    
      
        

      

      
        * *****Confidential material redacted and filed separately
with the Commission.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              7.2

            	
              All
      applications to be filed by the Licensors in accordance with the
      provisions of Section 7.1 above, shall be filed in the name of the
      Licensors or, should the law of the relevant jurisdiction so require, in
      the name of the inventor and then assigned to the Licensors. As of April
      2001, the Company shall bear all costs and fees incurred by the Licensors
      in the preparation, filing, prosecution, and the like of all patent
      applications filed in accordance with the provisions of Section 7.1 above
      and in the maintenance, protection at the appropriate patent office and
      the like of all patents issuing therefrom, as well as of the existing
      patents, if any, or, if so instructed by the Licensors, shall pay all
      costs and fees relating to such patent applications directly to the third
      parties to whom they are due, as they come due. The Company agrees to pay
      any amounts due to the Licensors or third parties pursuant hereto within
      30 (thirty) days of the Licensors’ first written request. Upon request by
      the Company, the Licensors shall submit to the Company receipts or other
      appropriate documents evidencing such costs and fees. For the avoidance of
      doubt, other than amounts already paid by the Company the Licensors shall
      not be entitled for reimbursement for out-of-pocket costs and fees
      incurred prior to the Effective Date in connection with the Existing
      Patent Applications and the existing patents included in the
      Patents.

            

    

     

    
      	
              7.3

            	
              In
      the event that, following such consultations between the parties regarding
      the filing of patent applications pursuant to Section 7.1 above, the
      Company shall not wish to file and/or continue to prosecute a patent
      application in relation to any part of the Licensed Information, then the
      Licensors may file and/or continue to prosecute such specific patent
      application at their own cost and expense. In such event, the License
      shall automatically expire with respect to the subject matter of such
      patent application (or patent) in the country or countries in which it is
      being filed and/or prosecuted, and the Licensors shall be entitled to
      freely exploit such patent application and associated portions of the
      Licensed Information in such country or countries as they see fit,
      including by granting licenses with respect thereto to third parties in
      such country or countries. The Company shall be entitled to subsequently
      renew the License with respect to any such patent application (or patent)
      in any such country or countries, provided that the Licensors have not
      granted rights with respect to such patent application or patent to a
      third party, by reimbursing the Licensors for the Licensors’ aggregate
      out-of-pocket costs and fees (as supported by receipts or other
      appropriate documents evidencing such costs and fees) incurred in
      connection with the said patent application (in the preparation, filing,
      prosecution, maintenance and the like of such application) and in
      connection with the patent received as aforesaid as a result of such
      application (in the maintenance, protection and the like of such patent),
      such costs and fees to be expressed in the currency in which paid by the
      Licensors and to be reimbursed by the Company to the Licensors in US
      Dollars , as well as interest thereupon for the period from the date of
      such payments by the Licensors until the date on which they are
      reimbursed, in accordance with the provisions relating to late payments
      set forth in Section 14 below. The Company shall bear all additional and
      future expenses relating to such patent application or patent, and the
      provisions of Section 7.2 shall apply as if the relevant patent
      application had been filed in accordance with Section 7.1
      above.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              7.4

            	
              Nothing
      herein contained shall be deemed to be a warranty by the Licensors that
      they can or will be able to obtain any patent or patents on any Patent
      Application or applications relating to the Licensed Information or any
      portion thereof, or that the Patents or any patents obtained on any of the
      said patent applications, if obtained, are or will be valid or will afford
      proper protection.

            

    

     

    
      	
              7.5

            	
              (a)

            	
              Each
      party shall promptly notify the other in writing of any alleged
      infringement or misappropriation by third parties of the Licensed
      Information and provide any information available to that party relating
      to such alleged infringement or
misappropriation

            

    

     

    
      	
               
      

            	
              (b)

            	
              Should
      the Company (i) determine that a third party is infringing one or more of
      the Patents, by manufacturing, using or selling any Product; or (ii) be
      sued on the grounds that the manufacture, use or sale of a Product by it
      or by a Sublicensee infringes upon the patent rights of a third party,
      then the Company shall be entitled to sue for such infringement or defend
      such action (as the case may be), and, to the extent required by the
      relevant law, the Licensors shall consent to being named as a party in any
      such litigation and shall cooperate with the Company, its attorneys and
      its agents, and upon request, provide the Company with the complete copies
      of any and all documents or other materials that the Company may
      reasonably deem necessary in order to undertake such responsibilities and
      shall use its best efforts to cause the Chief Investigators to cooperate
      with the Company in prosecuting or defending such litigation, provided
      that any expenses or costs incurred in connection with such litigation
      (including, without limitation, legal costs and other sums awarded to the
      counter party in such action) shall be borne by the Company, who (without
      derogating from the provisions of Section 13 below) shall indemnify the
      Licensors against any such expenses or
costs.

            

    

     

    
      
        	
              	
                (c)

              	
                In
      the event that the Company receives any monetary awards due to action or a
      suit, then such monetary awards shall be allocated to defray the costs and
      expenses (including reasonable attorneys’ fees) incurred by the Company,
      and any remaining balance will be divided as follows:
    *****.

              

      

    

     

    
      	
               
      

            	
              (d)

            	
              Notwithstanding
      that stated in subsection (b) above, the Company shall not be entitled to
      oblige the Licensors to take any action whatsoever for the protection of
      or against infringement of any Patents. In the event that the Company
      shall not exercise its right under this Section 7.6, any action of the
      Licensors shall be entirely at the Licensors’ discretion, and the costs of
      any such action, as well as any costs or other sums awarded to any
      counter-party in such action, shall be paid by the Licensors exclusively,
      and any recovery in any such action shall be retained exclusively by the
      Licensors.

            

    

    
       

      
        

      

      
        * *****Confidential material redacted and filed separately
with the Commission.

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              8. 

            	
              License

            

    

     

    
      	
              8.1

            	
              The
      Licensors hereby grants to the Company and the Company hereby accepts from
      the Licensors, an exclusive worldwide license under the Patents and the
      Licensed Information for the development, use, marketing, distribution and
      sale of the Products, and, to the extent to which such rights are covered
      by an applicable Patent, to manufacture the Products (“the License”), all
      for such period, for such consideration and upon such terms and conditions
      as are set forth in this Agreement. The License granted herein, and the
      use of the terms “Product” or “Products” in connection therewith, shall
      apply to the treatment in human patients of myeloma, and to any other
      additional cancer indications within the scope of the Patents and the
      Licensed Information with respect to which the Company has submitted to
      the Licensors a satisfactory detailed research and development plan
      including a timetable and budget substantially similar to Attachments C
      and D hereto (each an “Additional Indication”). The term of the License
      with respect to such Additional Indication shall commence upon the
      confirmation by the Licensors that an appropriate research and development
      program has been submitted by the Company and extend for the period set
      forth in Section 8.2 below and all undertakings, obligations, liabilities
      and responsibilities hereunder shall apply also to such Additional
      Indication (myeloma and any Additional Indication shall be referred to
      hereunder as an “Indication”). For the avoidance of any doubt, the
      Licensors shall be entitled to freely grant licenses to third parties
      under the Patents and the Licensed Information relating to the treatment
      of any medical indication that is not an
  Indication.

            

    

     

    
      	
              8.2

            	
              The
      License shall remain in force with respect to any of the Products for each
      particular Indication in any country (if not previously terminated
      according to the provisions of this Agreement) as
  follows:

            

    

     

    
      	
              8.2.1

            	
              In
      a country where a Patent or Patents has been issued relating to such
      Product, until the latter of (i) the date of expiry of the Patent (or the
      last of the Patents) covering such Product in such country or (ii) the
      fifteenth (15th) anniversary of the date of the First Commercial Sale by
      the Company (or a Sublicensee) in such
country;

            

    

     

    
      	
              8.2.2

            	
              In
      any other country, upon the fifteenth (15th) anniversary of the date of
      the First Commercial Sale (with respect to such Indication) by the Company
      (or a Sublicensee) in such country.

            

    

     

    
      
        	
                8.2.3

              	
                The
      Company shall promptly notify the Licensors in writing upon the occurrence
      of a First Commercial Sale for any given Product, specifying the date, the
      country in which such sale took place and the type of Product
      sold.

              

      

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              9.

            	
              Sublicense

            

    

     

    
      	
              9.1

            	
              A
      sublicense to all or any portion of the rights granted under the License
      (a “Sublicense”)
      may be granted by the Company only if: (1) the proposed sublicense is for
      monetary consideration or its equivalent (ii) the proposed sublicense is
      to be granted in a bona fide arms-length commercial transaction,
      including, for the avoidance of doubt, a bona fide subcontracting
      agreement for the manufacture of a Product by a third party on the
      Company’s behalf (to the extent that the Company has received a license to
      manufacture such Product from the Licensors) , and (iii) the proposed
      sublicense is made by written agreement, whose provisions are consistent
      with the terms of the License and contain, inter alia, the following terms
      and conditions:

            

    

     

    
      	
            	
              9.1.1

            	
              The
      Sublicense shall expire automatically on the termination of the License
      for any reason;

            

    

     

    
      	
            	
              9.1.2

            	
              The
      Sublicensee shall undertake in writing to the Licensors to be bound by
      provisions substantially similar to those contained in Sections 11 and 13
      below;

            

    

     

    
      	
            	
              9.1.3

            	
              Such
      terms necessary to enable performance by the Company of its obligations
      hereunder;

            

    

     

    
      	
            	
              9.1.4

            	
              Any
      act or omission by the Sublicensee which would have constituted a breach
      of this Agreement by the Company had it been committed (or failed to be
      performed) by the Company, shall constitute a breach of the sublicense
      agreement with the Company entitling the Company to terminate the
      sublicense.

            

    

     

    
      	
            	
              9.1.5

            	
              The
      sublicense shall not be assignable, transferable or subject to further
      sublicensing without the express prior written consent of the
      Licensors;

            

    

     

    
      	
              9.2

            	
              Sublicenses
      under the License may be granted by the Company to Affiliated Entities of
      the Company, provided that, in addition to the terms and conditions listed
      in Sections 9.1.1. to 9.1.5 above, the sublicense agreement shall
      stipulate that the sublicense shall automatically expire in the event that
      the Sublicensee ceases to be an Affiliated Entity of the
      Company;

            

    

     

    
      
        	
                9.3

              	
                A
      copy of the proposed agreement granting a sublicense pursuant to Sections
      9.1 or 9.2 above
      shall be submitted to each of the Licensors for review at least twenty-one
      (21) days prior to its execution, and an executed copy shall be provided
      to each of the Licensors promptly upon execution
      thereof.

              

      

    

     

    
      	
              9.4

            	
              The
      Company hereby undertakes to promptly inform the Licensors upon receipt of
      knowledge by the Company of any breach of the sublicense agreement by a
      Sublicensee, and, if so requested by the Licensors, to exercise the
      Company’s right of termination under said agreement with the
      Sublicensee.

            

    

     

    
      	
              10.

            	
              Consideration

            

    

     

    
      
        	
              	
                10.1.1

              	
                The
      Company shall pay to Yeda a license grant fee of ***** (the “License Grant
      Fee”).

              

      

    

    
       

      
        

      

      
        * *****Confidential material redacted and filed separately
with the Commission.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        	
              	
                10.1.2.

              	
                The
      License Grant Fee shall be payable in four installments, the first of
      which shall be in the amount of *****, due and payable upon completion of
      three months from the Effective Date; the second of which shall be in the
      amount of *****, due and payable upon completion of four months from the
      Effective Date; the third of which shall be in the amount of *****, due
      and payable upon the completion of eight months from the Effective Date;
      and the fourth of which shall be in the amount of *****, due and payable
      upon the completion of twelve (12) months from the Effective Date. The
      first and second installments (in the total amount of ***** shall be
      payable regardless of the prior termination of this agreement for any
      reason whatsoever, however the payment of the third and fourth
      installments shall not apply in the event that this Agreement has been
      terminated in accordance with the terms and conditions of this Agreement
      prior to the date upon which such payment is due. All payments of the
      License Grant Fee hereunder shall be made in US
  dollars.

              

      

    

     

    
      	
              10.2

            	
              Annual
      License Fees.

            

    

     

    
      	
            	
              10.2.1

            	
              In
      addition to the License Grant Fee, the Company shall pay to Yeda an annual
      license fee of ***** per year (“Annual License Fee”),
      subject to the terms and conditions set out in this Section 10.2 and
      Section 14 below.

            

    

     

    
      
        	
              	
                10.2.2

              	
                The
      initial payment of Annual License Fees shall be due and payable upon the
      first anniversary of the Effective
Date.

              

      

    

     

    
      
        	
              	
                10.2.3

              	
                Subsequent
      Annual License Fees shall be payable on each anniversary of the Effective
      Date thereafter, for the duration of the period in which the License is in
      effect.

              

      

    

     

    
      
        	
              	
                10.2.4

              	
                Upon
      receipt of Product Approval, during the term of the License, the Annual
      License Fees shall be increased to ***** per
  year.

              

      

    

     

    
      	
              10.3

            	
              Payment Upon Approval
      of Patents. In addition, the Company shall pay to Yeda a one-time
      payment of ***** upon the later of (i) the first anniversary of the
      Effective Date or (ii) within fourteen (14) days of issuance or
      registration of the first Patent registered hereunder. For the removal of
      doubt, Yeda shall not be entitled to receive any payment upon the approval
      of any subsequent Patent.

            

    

     

    
      	
              10.4

            	
              Payment upon Product
      Approval. In addition, the Company shall pay to Yeda a onetime
      payment of *****, within fourteen (14) days of receipt of the Product
      Approval for the first Product. To remove doubt, Yeda shall be entitled to
      payment under this Section 10.4 once, for the first Product to receive
      Product Approval only.

            

    

     

    
      	
              10.5

            	
              Payment upon an
      Entitling Event. In addition, within fourteen (14) days of receipt
      of the proceeds from an Entitling Event, Yeda shall be entitled to receive
      from the Company an/or other member(s) of the Biogal Group and/or
      its/their shareholders (as the case may be) *****. Notwithstanding the
      aforesaid, if the consideration paid in the Entitling Event is in the form
      of securities of a third party, Yeda will be entitled to receive such
      number of the same type of securities being offered in the Entitling Event
      having equal value to the cash consideration to which Yeda is entitled
      hereunder for such Entitling Event. In the event that the consideration
      received in the context of an Entitling Event is payable in installments,
      Yeda shall be entitled to receive payments from each installment paid in
      accordance with the provisions of this Section 10.5, until its entitlement
      to payment hereunder has been fully
satisfied.

            

    

     

    
      

    

    
      
        * *****Confidential material redacted and filed separately
with the Commission.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              10.6

            	
              Acknowledgement by
      Mor. Mor acknowledges and confirms that it has been issued an
      equity interest in the Company in consideration of the granting of the
      License, and accordingly, shall not be entitled to any additional fee or
      payment for the granting of the License. The foregoing shall not derogate
      in any manner from Mor’s entitlement to receive funds hereunder in
      connection with the Initial Research (or in connection with any further
      Research or services it may provide to a member of the Biogal
      Group).

            

    

     

    
      	
              11.

            	
              Confidentiality

            

    

     

    
      	
              11.1

            	
              Each
      member of the Biogal Group shall maintain in confidence of all
      confidential information relating to the Research and all technical,
      medical, financial or other information or data relating to the Licensed
      Information, or to any patent applications included in the Patents, except
      and to the extent that :(a) any such information or data is in the public
      domain at the date of the signing hereof or becomes part of the public
      domain thereafter (other than through a violation by the Company or a
      Sublicensee of this obligation of confidentiality); or (b) such
      confidential information (or any portion thereof) that is expressly
      released by the Licensors from this obligation of confidentiality by
      notice in writing to the Company to such effect; or (c) the Licensed
      Information was received by the Company from a third party legally
      entitled to disclose it without breach of a confidentiality undertaking to
      Yeda. Notwithstanding the foregoing, the Company may disclose to its
      personnel and other third parties (including Sublicensees) the Licensed
      Information to the extent necessary for the exercise by it of its rights
      hereunder or in the fulfillment of its obligations hereunder, provided
      that such personnel and other third parties shall be subject to written
      confidentiality undertakings no less strict than those contained
      herein.

            

    

     

    
      	
              11.2

            	
              The
      Licensors shall maintain in confidence of all information and data
      received from the Company and explicitly identified in writing as
      confidential, except and to the extent that: (a) any such information or
      data is in the public domain at the date of the signing hereof or becomes
      part of the public domain thereafter (other than through a violation by
      the Licensors of this obligation of confidentiality); or (b) any such
      information or data is expressly released by the Company from this
      obligation of confidentiality by notice in writing to the Licensors to
      such effect; or (c) the information was rightfully received by the
      Licensors from a third party without any restrictions on disclosure or
      use. Notwithstanding the foregoing, the Licensors may disclose to its
      personnel any such confidential information or data to the extent
      necessary for the exercise by it of its rights hereunder or in the
      fulfillment of its obligations hereunder, provided that such personnel
      shall be subject to written confidentiality undertakings no less strict
      than those contained herein.

            

    

     

    
      	
              11.3

            	
              In
      addition to and without derogating from the foregoing, the Company
      undertakes not to make mention of the names of Yeda, Mor, the Institute or
      any scientists or other employee thereof in any manner or for any purpose
      whatsoever in relation to this Agreement, its subject matter and any
      matter arising from this Agreement or otherwise, without the prior written
      approval of Yeda or Mor (as applicable) which will not be unreasonably
      withheld.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              11.4

            	
              Notwithstanding
      the provisions of Sections 11.1, 11.2 and 11.3 above, the Company shall
      not be prevented from mentioning the name of Yeda, Mor, the Institute, or
      any hospital or medical institute which was involved in the Research
      and/or any scientists or other employees thereof or from disclosing any
      information:

            

    

     

    
      	
               
      

            	
              (a)

            	
              If,
      and to the extent that such mention or disclosure (i) is to competent
      authorities for the purposes of obtaining approval or permission for the
      exercise of the License, or is in the fulfillment of any legal duty owed
      to any competent authority (including, without limitation, a duty to make
      regulatory filings); or (ii) is the fact of the execution of this
      Agreement to any third party; or (iii) relates to any information relating
      to this Agreement (to the extent necessary and to the extent such
      information does not constitute Licensed Information or any other
      information that the Company is obliged to maintain in full confidence
      pursuant to clause 11.1 above); or

            

    

     

    
      	
               
      

            	
              (b)

            	
              In
      the event of (i) a private placement; or (ii) an initial public offering
      of shares of the Company; or (iii) a merger or acquisition of the Company,
      the Company will be authorized to disclose any information to any
      prospective investor or any other relevant party, subject to the written
      undertaking of confidentiality addressed to the Company in a form
      reasonably acceptable to the Licensors, of such prospective investor or
      recipient of such information (and provided that it shall be clearly
      indicated any document so provided to such a party, that Yeda has not
      reviewed or approved the information so provided);
  or

            

    

     

    
      	
               
      

            	
              (c)

            	
              The
      Company shall be entitled to mention that the Company is a Licensee of
      Yeda and Mor to develop, use, market, manufacture (if applicable), sell
      and distribute the Products, in any business presentations, press
      interviews, brochures and company profiles, copies of which shall be
      provided to the Licensors within a reasonable time of printing,
      publication or disclosure thereof.

            

    

     

    
      	
              11.5

            	
              The
      termination of this Agreement for any reason whatsoever, shall not release
      the Company from any of its obligations under this Section 11 and such
      obligations shall survive any such
termination.

            

    

     

    
      	
              11.6

            	
              Yeda,
      the Institute and the scientists of the Institute may publish articles
      relating to the Licensed Information in scientific journals or posters or
      to give lectures or seminars to third parties relating to the Licensed
      Information, or in any other way to publish the Research or the results
      thereof, on condition that, to the extent that the information to be
      published or disclosed is not in the public domain, a draft copy of the
      said contemplated publication or disclosure shall have been furnished to
      the Company at least sixty (60) days before the making of any such
      publication or disclosure and the Company shall have failed to notify Yeda
      in writing, within thirty (30) days from receipt of the said draft
      publication or disclosure, of its opposition to the making of the
      contemplated publication or disclosure. Should the Company notify Yeda in
      writing within thirty (30) days from the receipt of the draft contemplated
      publication or disclosure that it opposes the making of such publication
      or disclosure because it includes material information (which has been
      specified in said notice), in respect of which there are reasonable
      grounds, such grounds also to be specified in the said-notice, requiring
      the preventing or postponement, as the case may be, of such publication or
      disclosure so as not adversely to affect the patentability of the Licensed
      Information, then Yeda shall not permit such publication or disclosure
      unless there shall first have been filed an appropriate patent application
      in respect of the material information to be published or disclosed as
      aforesaid, and if this cannot reasonably be undertaken, then Yeda shall
      not permit such publication or disclosure unless the material information
      specified in the Company’s notice as aforesaid has been deleted therefrom.
      The Company acknowledges that it is aware of the importance to the
      researchers of publishing their work and, accordingly, the Company will
      use its best efforts not to oppose such
  publications.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              12.

            	
              No
      Assignment

            

    

     

    
      	
               
      

            	
              The
      Company may assign, transfer or encumber all or any of its rights or
      obligations under this Agreement or arising therefrom, provided it has
      received the prior written consent of both of the Licensors, which shall
      not be unreasonably withheld. A Licensor opposing such assignment,
      transfer or encumbrance of rights, shall provide the Company with a
      written explanation of the grounds for its opposition. The Licensors shall
      be entitled to condition their consent to an assignment inter alia on the
      receipt of written assurances and/or guarantees (including an undertaking
      by the Company to guarantee payment of all fees and payments due hereunder
      to Yeda).

            

    

     

    
      	
               
      

            	
              Notwithstanding
      the foregoing, the Company shall be entitled to make an assignment of all
      (but not part) of its rights and obligations under this Agreement to an
      Affiliated Entity without prior written consent of the Licensors, provided
      that: (i) prior written notice of such intended assignment, together with
      the copy of the agreement of the proposed assignment shall be submitted to
      the Licensors at least 30 (thirty) days before signing; (ii) the terms of
      the assignment shall ensure that it shall be consistent with the
      provisions of this Agreement and will not derogate in any manner from the
      rights of the Licensors hereunder; (iii) the assignment shall expire
      automatically if the assignee ceases to be an Affiliated Entity of the
      Company; (iv) the Affiliated Entity shall assume all obligations of the
      Company under this Agreement without releasing the Company of its
      obligations hereunder. Any assignment or attempted assignment contrary to
      the provisions hereof shall be null and
void.

            

    

     

    
      	
              13.

            	
              Exclusion
      of Liability and
Indemnification

            

    

     

    
      	
              13.1

            	
              Yeda,
      Mor, the Institute, RMC and the directors, officers and employees thereof
      (hereinafter collectively “the Indemnitees”) shall
      not be liable for any claims, demands, liabilities, costs, losses, damages
      or expenses (including legal costs and attorney’s fees) of whatever kind
      or nature caused to or suffered by any person or entity (including,
      without limitation, to the Company or any Sublicensee) that directly or
      indirectly arises out of or result from or are encountered in connection
      with this Agreement or the exercise of the License, including, without
      limiting the generality of the foregoing, directly or indirectly arising
      out of or resulting from or encountered in connection with the
      development, manufacture, sale or use of any Product by any member of the
      Biogal Group, any Sublicensee or any person acting in the name of or on
      behalf of any of the foregoing, or acquiring any of the Products from any
      of the foregoing, or directly or indirectly arising out of or resulting
      from or encountered in connection with the exploitation or use by any
      member of the Biogal Group or any Sublicensee of the Licensed Information
      or any part thereof, including, without limitation, of any data or
      information given, if given, in accordance with this
      Agreement.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              13.2

            	
              In
      the event that any of the Indemnitees should suffer any damages, claim,
      demand, liability, loss, cost or expense as aforesaid in Section 13.1, or
      shall be requested or obliged to pay to any person or entity any amount
      whatsoever as compensation for any damages, demand, claim, liability,
      cost, loss or expense as aforesaid, then the Company, the Biogal Group
      and/or each of their successors or assigns (each jointly and severally)
      shall defend, indemnify and hold harmless such Indemnitees from and
      against any and all such damages, claim, demand, liability, cost, loss or
      expense (including attorney fees and legal costs) of whatever kind or
      nature as aforesaid. Without limiting the generality of the foregoing, the
      foregoing indemnification and the exclusion of liability set forth in
      Section 13.1 above shall extend to product liability claims and to
      damages, claims, demands, liabilities, losses, costs and expenses
      attributable to death, personal injury or property damage or to penalties
      imposed on account of the violation of any law, regulations or
      governmental requirement. Notwithstanding the foregoing, the Company, the
      Biogal Group shall have no obligation to indemnify an Indemnitee in the
      event and to the extent that any damages, claim, liability, demand, loss,
      cost or expense as aforesaid results from the fraudulent misconduct of
      such Indemnitee.

            

    

     

    
      	
              13.3

            	
              The
      Company and Biogal Israel shall each, at its own expense, insure its
      liability pursuant to Section 13.2 above during the period beginning on
      the date of (i) the commencement of the clinical trials of a Product in
      any country or in-vivo research, in the case of Products which are drugs,
      or (ii) the first sale by a member of the Biogal Group (whether commercial
      or for experimental or test-market purposes) in the case of any other
      Product, for the entire period that the License is in force, and for an
      additional ***** thereafter. Such insurance shall be in reasonable amounts
      and on reasonable terms in the circumstances, having regard, in
      particular, to the nature of the Products, and shall be subscribed for
      from a reputable insurance company. The beneficiaries of such insurance
      shall be the Company, Yeda and Mor. The policy or policies so issued shall
      include a “cross-liability” provision pursuant to which the insurance is
      deemed to be separate insurance for each insured party (without right of
      subrogation as against any of the insured under the policy, or any of
      their representatives, employees, officers, directors or anyone in their
      name) and shall further provide that the insurer will be obliged to notify
      each insured in writing at least 60 days in advance of the expiry or
      cancellation of the policy or policies. The Company hereby undertakes to
      comply with all obligations imposed upon it under such policy or policies
      and in particular, without limiting the generality of the foregoing, to
      pay in full all premiums and other payments for which it is liable
      pursuant to such policy or policies. The Company shall be obliged to
      submit to the Licensors, upon issuance, copies of the aforesaid insurance
      policy or policies.

            

    

     

    
      	
              13.4

            	
              The
      provisions of this Section 13 shall survive the termination of this
      Agreement for any reason
whatsoever.

            

    

     

    
      	
              14.

            	
              Term
      and Termination

            

    

     

    
      	
              14.1

            	
              Term.
      Unless previously terminated in accordance with the provisions hereof,
      this Agreement shall terminate upon the expiration of the
      License.

            

    

     

    
      

    

    
      
        * *****Confidential material redacted and filed separately
with the Commission.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              14.2

            	
              Termination

            

    

     

    
      	
            	
              14.2.1

            	
              Without
      derogating from the parties’ rights hereunder or by law, to any other or
      additional remedy or relief, it is agreed that each of the Licensors or
      the Company may terminate this Agreement and the License hereunder by
      serving a written notice, effective immediately, on the infringing party
      upon  the occurrence of:(a) a material breach hereof by the
      other (which breach cannot be cured or, if curable, has not been cured by
      the party in breach within ***** or, in the case of failure by the Company
      to pay any amount due by the Company to Yeda pursuant to or in connection
      with this Agreement on or before due date of payment, thirty (30) days
      after receipt of a written notice from the other party in respect of such
      breach, and in such event this Agreement and the License hereunder shall
      be terminated forthwith upon receipt of notice as
    aforesaid.

            

    

     

    
      
        	
              	
                14.2.2

              	
                Without
      derogating from the provisions of Section 14.2.1 above, each of the
      Licensors shall be entitled to cancel this Agreement (including the
      License hereunder) with immediate effect, by delivery of a written notice
      to such effect to the
Company:

              

      

    

     

    
      
        	
              	
                14.2.2.1

              	
                If
      the Company (or a permitted Sublicensee) shall not within ***** of the
      date of expiry of the Initial Research Period have received a Product
      Approval and/or commenced the commercial sale or manufacture, of a
      Product, or shall cease such manufacture or sale for a period of more than
      twelve (12) months, provided however, that such period shall be extended
      if the cessation of the manufacture or sale results solely from an act or
      omission of a third party, which the Company cannot remedy or repair by
      other means, and of which the Company has informed the Licensors in
      writing not less than three months from its occurrence or non-occurrence
      (the “Preventing Event”), for as long as the Preventing Event exists, but
      not to extend more than twenty-four (24)
months.

              

      

    

     

    
      
        	
              	
                14.2.2.2

              	
                If
      the Company shall not have received additional funding for the continued
      development of the Products of at least ***** of the Effective Date, at
      least ***** of which shall be allocated to research and development
      activities of the Company.

              

      

    

     

    
      
        	
              	
                14.2.2.3

              	
                Upon
      the filing of a petition in bankruptcy, liquidation, insolvency,
      reorganization or receivership that is not dismissed within sixty (60)
      days of the date on which it is filed against or by the Company and/or
      Biogal Israel and/or an Affiliated Entity Sublicensee thereof, or if any
      of the foregoing shall be subject to an arrangement with creditors,
      whether by law or agreement, or shall otherwise becoming
      insolvent.

              

      

    

     

    
      
        

      

      
        * *****Confidential material redacted and filed separately
with the Commission.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      
        	
              	
                14.2.2.4

              	
                Upon
      the assignment or transfer of this Agreement or any rights or obligations
      hereunder by the Company and/or Biogal Israel and/or an Affiliated Entity
      Sublicensee thereof in contravention of the provisions of this
      Agreement.

              

      

    

     

    
      
        	
              	
                14.2.2.5

              	
                Upon
      termination of the Founders Agreement for any reason, or upon the
      occurrence of an event which would entitle either Licensor to terminate
      the Founders Agreement.

              

      

    

     

    
      
        	
              	
                14.2.3

              	
                For
      the purposes of this Section 14.2, a notice of termination of this
      Agreement sent by either Yeda or Mor to the Company shall be deemed in all
      circumstances to have been jointly issued by both of the
      Licensors.

              

      

    

     

    
      	
              14.3

            	
              The
      Company shall be entitled, on the giving to the Licensors of one hundred
      and twenty (120) days prior written notice to such effect, to terminate
      this Agreement, in the event that the Company considers that for
      scientific, medical, or commercial reasons, the development of any Product
      is not feasible, provided that: (1) such termination shall not take effect
      prior to the termination of the Initial Research Period, provided however,
      that the Company may terminate this Agreement for sufficient scientific,
      medical or commercial grounds upon the completion of a period of *****
      from the Effective Date, with three (3) months prior written notice to the
      Licensors, if no Product is being marketed, distributed or sold at such
      time and (ii) the Company shall continue, after termination of this
      Agreement in accordance with the foregoing, to be liable for all expenses
      and costs incurred by the Licensors prior to the termination of the
      Agreement, in respect of the Initial Research Program or the Research
      Program within the scope of the Initial Research Budget or the Research
      Budget (or any mutually agreed upon extension thereof) which Yeda or Mor
      is not entitled to cancel (pursuant to law or contract) and all costs and
      expenses incurred by either of the Licensors, prior the termination of
      this Agreement in connection with the Patents pursuant to Section 7.1
      above. The provisions of Section 14.3(ii) shall survive termination of
      this Agreement.

            

    

     

    
      	
              14.4

            	
              Upon
      the termination of this Agreement for whatever reason, all of the
      Company’s rights hereunder in and to the Licensed Information shall revert
      to the Licensors and the Company or other members of Biogal Group shall
      not be entitled to make any further use of the Licensed Information and
      the Company and other members of the Biogal Group shall deliver to the
      Licensors all drawings, plans, diagrams, specifications, other
      documentation, models or any other physical matter in their possession in
      any way containing, representing or embodying the Licensed Information.
      Notwithstanding the foregoing, the Company may retain copies of all such
      documentation relating to any development and other work performed by the
      Company in connection with the Products provided that: (i) such
      documentation may be used by the Company for the sole purpose of defending
      itself in any future claims relating to the exercise by the Company (prior
      to termination) of its rights hereunder; (ii) the Company shall otherwise
      maintain such documentation in strict confidence as long as the obligation
      of confidentiality under Section 11 shall continue to apply thereto; and
      (iii) the retention of such documentation shall in no way be deemed to
      establish any right to the further exercise of the License or of the
      Licensed Information.

            

    

     

    
      

    

    
      
        * *****Confidential material redacted and filed separately
with the Commission.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              14.5

            	
              The
      termination of this Agreement for any reason shall not relieve the parties
      of any obligations, which shall have accrued prior to such
      termination.

            

    

     

    
      	
              15.

            	
              Late
      Payments

            

    

     

    
      	
               
      

            	
              Any
      amount payable hereunder by one of the parties to another, that has not
      been paid by its due date of payment shall bear interest from its due date
      of payment until the date of actual payment, at the average LIBOR rate for
      Dollar deposits for a period of 3 (three) months prevailing from time to
      time during the period of arrears, *****.

            

    

     

    
      	
              16.

            	
              Notices.

            

    

     

    
      	
               
      

            	
              Any
      notice to be given pursuant to or in connection with this Agreement shall
      be given, in writing, by facsimile or by prepaid registered mail, to the
      following address (or such other address in Israel as a party may from
      time to time notify the other parties hereto in writing shall serve as its
      address for this purpose):

            

    

     

    For Yeda:
To the address set forth in the Preamble,

    Fax: 08-9470739.

     

    For Mor:
To the address set forth in the Preamble.

    Fax: 03-9233228

     

    For the
Company and/or Biogal Israel:

     

    and shall
be deemed to be received by such party: (a) if sent by courier, upon receipt;
(b) if sent by facsimile, on the first business day after the date of
transmission or (c) if by registered letter (or nearest equivalent), four (4)
days after the time at which it was posted.

     

    
      	
              17.

            	
              Guarantee.

            

    

     

    
      	
               
      

            	
              The
      Company hereby undertakes to serve as guarantor for the full and timely
      performance by the Company and/or Biogal Israel of all of its/their
      obligations hereunder, including without limitation, the full and prompt
      payment of all fees and payments (including license fees and payments,
      payment of the Research Budget and the reimbursement of costs and
      expenses) due to Yeda and Mor under this
  Agreement.

            

    

     

    
      

    

    
      
        * *****Confidential material redacted and filed separately
with the Commission.

         

      

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    
      	
              18.

            	
              Value
      Added Tax.

            

    

     

    
      	
               
      

            	
              Each
      party shall reimburse the other party against submission of appropriate
      tax invoices, all amounts of Value Added Tax imposed on such other party
      in connection with the transactions under this
  Agreement.

            

    

     

    
      	
              19.

            	
              Miscellaneous.

            

    

     

    
      	
              19.1

            	
              Entire
      Agreement. This Agreement and the Founders Agreement constitutes
      the entire agreement between the parties hereto in respect of the subject
      matter hereof, and supersedes all prior agreements or understandings
      between the parties relating to the subject matter hereof, and this
      Agreement may be amended only by a written document signed by both parties
      hereto.

            

    

     

    
      	
              19.2

            	
              Counterparts.
      This Agreement may be signed in any number of counterparts, no one of
      which need be signed by more than one party, and all such copies, when
      duly executed, shall be considered an original of one and the same
      document.

            

    

     

    
      	
              19.3

            	
              Waiver. No
      waiver by any party hereto, whether express or implied, of its rights
      under any provision of this Agreement shall constitute a waiver of such
      party's rights under such provisions at any other time or a waiver of such
      party's rights under any other provision of this Agreement. No failure by
      any party hereto to take any action against any breach of this Agreement
      or default by another party hereto shall constitute a waiver of the former
      party's rights to enforce any provision of this Agreement or to take
      action against such breach or default or any subsequent breach or default
      by such other party.

            

    

     

    
      	
              19.4

            	
              Governing Law;
      Venue. This Agreement shall be governed in all respects by the laws
      of Israel, and the courts of Israel shall have exclusive jurisdiction over
      all disputes arising hereunder

            

    

     

    
      	
              19.5

            	
              Independent
      Contractors. Nothing contained in this Agreement shall be construed
      to place the parties in relationship of partners or parties to a joint
      venture or to constitute either party an agent, employee or legal
      representative of the other party and neither party shall have power or
      authority to act on behalf of the other party or to bind the other party
      in any manner whatsoever.

            

    

     

    
      	
              19.6

            	
              Severability.
      In the event that any provision of this Agreement is held invalid or
      unenforceable in any circumstances by a court of competent jurisdiction,
      the remainder of this Agreement, and the application of such provision in
      any other circumstances, shall not be affected
  thereby.

            

    

     

    
      	
              19.7

            	
              No Set-Off. All
      payments to be made to the Licensors hereunder shall be made free and
      clear of and without any deduction for or on account of any set-off,
      counterclaim or tax.

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    IN
WITNESS WHEREOF the parties hereto have set their signatures as of this 7th day
of January, 2002.

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            
                                              
                                                	
                                                        YEDA
      RESEARCH AND

                                                        DEVELOPMENT
      COMPANY LTD

                                                      	 
      	
                                                        MOR
      RESEARCH APPLICATIONS

                                                        LTD.

                                                      
	 
      	 
      	 
      
	
                                                        By:

                                                      	 
      	 
      	
                                                        By:

                                                      	 
      
	 
      	 
      	 
      	 
      	 
      
	
                                                        Title:

                                                      	 
      	 
      	
                                                        Title:

                                                      	 
      
	 
      	 
      	 
      
	
                                                        HAVERFIELD
      LTD.

                                                      	 
      	 
      
	 
      	 
      	 
      
	
                                                        By:

                                                      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      
	
                                                        Title:

                                                      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      
	
                                                        BIOGAL
      ADVANCED BIOTECHNOLOGY LTD

                                                      	 
      	 
      
	 
      	 
      	 
      
	
                                                        By:

                                                      	 
      	 
      	 
      
	 
      	 
      	 
      	 
      
	
                                                        Title:CONFIDENTIAL TREATMENT
REQUESTED .  Confidential portions of this document have been redacted
and have been separately filed with the Commission.

    

    Exhibit
10.45

     

    AMENDMENT
TO THE RESEARCH AND LICENSE AGREEMENT

     

    This
Amendment effective as of April 1 2008 (the “Effective Date”) of the
Research and License Agreement dated January 7, 2002 (the “Research and License
Agreement”) entered into by and between Yeda Research And Development
Company Ltd., a company duly registered under the laws of Israel of P.O. Box 95,
Rehovot 76100, Israel (“Yeda”), Mor Research
Applications Ltd. a company duly registered under the laws of Israel and having
its principal place of business at 23 Hasivim Street., Kiryat Matalon, P.O. Box
7590 Petach Tikva 49170 (“Mor”) (Yeda and Mor shall be
collectively referred to as the “Licensors”); Biogal Ltd.
(under its previous name HaverfieId Ltd)., a company duly registered under the
laws of Gibraltar and having its principal place of business at Valmet Nominees
Limited Suites 7B & 8B 50 Town Range Gibraltar (the “Company”) and Biogal Advanced
Biotechnology Ltd., a company duly registered under the laws of the State of
Israel and having its principal place of business at 3 Hayezira St. Shap House,
Ramat Gan, Israel 52521 (“Biogal Israel”).

     

    WHEREAS,
the Licensors, Biogal Israel and the Company desire to amend the Research and
License Agreement (as has been several times amended during the years), in
accordance with the terms and conditions contained herein.

     

    All terms
used herein and not defined shall have the meaning ascribed to them in the
Research and License Agreement.

     

    NOW THEREFORE, the Parties hereto
hereby agree as follows:

     

    
      
        	
                1.

              	
                As
      of date, the principal amount of the Annual License Fee due to be paid to
      Yeda consist of ***** (the “Accumulated
      Annual Fee”). As previously agreed by Yeda and Company, such
      Accumulated Annual Fee bears an accumulated interest at the rate of *****
      (the “Interest”). The Accumulated
      Annual Fee plus accrued Interest was due to be paid to Yeda by the Company
      no later than *****.

              

      

    

     

    
      	
              2.

            	
              Commencing
      upon the Effective Date hereof, the Accumulated Annual Fee plus accrued
      Interest thereon (the “Due Payment”) shall be
      paid to Yeda within ***** of recipe of the proceeds from an Entitling
      Event, as such term is defined in the Research and License
      Agreement.

            

    

     

    The Due
Payment shall be paid in addition to any other amount payable to Yeda upon the
closing of an Entitling Event, as specified in Section 10.5 of the Research and
License Agreement.

     

    
      	
              3.

            	
              Commencing
      upon the Effective Date hereof, Section 10.2 of the Research and License
      Agreement, as amended from time to time, shall be replaced in its entirety
      with the following provisions;

            

    

    

    
      
        

      

    

    * *****Confidential material redacted and
filed separately with the Commission.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    (i) the
then current market conditions for such sale or, in the absence of such current
market conditions, according to market conditions for sale of products similar
to the Products; and

     

    (ii) with
respect to sales by the Company and for a Sublicensee, as applicable, to any
Affiliated Entity of the Company or of such Sublicensee, as the case may be, the
term, “Net Sales” shall
mean the higher of (A) “Net
Sales”, as defined in paragraph (a) above; and (B) the total amount
invoiced by such Affiliated Entity on resale to an independent third party
purchaser after the deductions specified in subparagraphs (i) and (ii) above, to
the extent applicable

     

    
      	
              4.

            	
              The
      Royalty Payment as aforesaid shall be paid in lieu of the Annual Licensee
      Fees referred to in Section 10.2 of the Research and License Agreement,
      which shall not be payable as of the Effective Date. The Royalty Payment
      shall be made by the Company (also on behalf of Sublicensees) for as long
      as the License under the Research and License Agreement is in
      force.

            

    

     

    
      	
              5.

            	
              The
      Company undertakes that all sales of Products by the Company and each
      Sublicensee shall be for cash consideration
  only.

            

    

     

    
      
        	
                6.

              	
                In
      calculating Net Sales all amounts shall be expressed in US Dollars and any
      amount received
      in a currency other than US Dollars shall be translated into US Dollars,
      for the purposes of calculation, in accordance with the applicable
      exchange rate between the US Dollar and such currency on the date of such
      receipt.

              

      

    

     

    
      “10.2 In
consideration for the grant of the License, the Company shall pay Yeda, 1% (one
percent) of Net Sales by or on behalf of the Company or by or on behalf of any
Sublicensee (the “Royalty
Payment”).

    

     

    The term
“Net Sales” shall mean
the total amount invoiced by the Company and the total amount invoiced by each
Sublicensee in connection with the sale of Products (for the removal of doubt,
whether such sales are made before or after the First Commercial Sale of any
Product in any country); in all cases after deduction of:

     

    
      	
               
      

            	
              (a)

            	
              sales
      taxes (including value added taxes) to the extent applicable to such sale
      and included in the invoice in respect of such
  sale;

            

    

     

    
      	
               
      

            	
              (b)

            	
              credits
      or allowances, if any, actually granted on account of price adjustments,
      recalls, rejections or returns of Products previously
  sold;

            

    

     

    
      	
               
      

            	
              (c)

            	
              Bad
      Debts, meaning invoices which have been recognized by the Company as bad
      debts and which amounts the Company’s accountants have agreed to include
      as bad debts in the Company’s financial statements in according with
      generally accepted accounting principles and in accordance with Israeli
      income tax regulations, and which derive from Net Sales in respect of
      which royalties were paid by the Company pursuant hereunder provided
      that:

            

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    (i) with
respect to sales which are not at arms-length and/or are not in the ordinary
course of business and/or are not according to then current market conditions
for such a sale, the term “Net
Sales” shall mean the total amount that would have been due in an
arms-length sale made in the ordinary course of business and according
to

     

    
      	
              7.

            	
              The
      Royalty payment shall be paid to Yeda in US Dollars no later than 45
      (forty five) days after the end of each calendar quarter, commencing with
      the first calendar quarter in which any Net Sales are made by the
      Company.

            

    

     

    
      	
              8.

            	
              Failure
      by the Company to fulfill its obligations under the terms of this
      Amendment shall be considered as a material breach of the Research and
      License Agreement, and Yeda shall be entitled, notwithstanding clause
      14.2.1 to the Research and License Agreement, to immediately terminate the
      Research and License Agreement and the License by serving a letter of
      termination on the Company.

            

    

     

    
      	
              9.

            	
              For
      the avoidance of doubt, Biogal Advanced Biotechnology Ltd. hereby
      undertakes to serve as guarantor for the full and timely performance by
      the Company of all of its obligations hereunder, including without
      limitation, the full and prompt payment of the total sum of the Due
      Payment and the Royalty Payments.

            

    

     

    
      
        	
                10.

              	
                This
      Amendment shall be effective upon execution by all those signatories
      thereof, effective
      as of the Effective Date.

              

      

    

     

    
      	
              11.

            	
              Except
      for those provisions, which are amended in accordance with the terms of
      this Amendment, the remainder of the terms and conditions of the Research
      and License Agreement, as has been amended from time to time, shall
      continue in full force and effect and shall, mutatis mutandis, apply to
      this Amendment.

            

    

     

    
      	
              12.

            	
              In
      any event of a conflict between and conditions contained in this Amendment
      and the Research and License Agreement, as has been amended from time to
      time, the terms contained in this Amendment shall
  govern.

            

    

     

    
      	
              13.

            	
              This
      Amendment may be executed in any number of counterparts, each of which
      shall be deemed an original and enforceable against the parties actually
      executing such counterpart, and all of which together shall constitute one
      and the same instrument. Facsimile signatures shall be binding as original
      signatures

            

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    IN
WITNESS WHEREOF the parties have signed this Agreement as of the date first
hereinabove set forth.

     

    
      
        	
                YEDA
      RESEARCH AND

                DEVELOPMENT
      COMPANY LTD.

              	 
      	
                MOR
      RESEARCH APPLICATIONS

                LTD.

              
	 
      	 
      	 
      
	
                By:    __________________________________________

              	 
      	
                By:    __________________________________________

              
	 
      	 
      	 
      
	
                Title:   _________________________________________

              	 
      	
                Title:   _________________________________________

              
	 
      	 
      	 
      
	
                 BIOGAL
      LTD.

              	 
      	
                BIOGAL
      ADVANCED BIOTECHNOLOGY

                LTD.

              
	 
      	 
      	 
      
	
                By:    __________________________________________

              	 
      	
                By:    __________________________________________

              
	 
      	 
      	 
      
	
                Title:   _________________________________________

              	 
      	
                Title:   _________________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]